IRIDEX (NASDAQ:IRIX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX) in a research report issued on Wednesday. The firm set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Price Performance

IRIX opened at $1.74 on Wednesday. The firm has a market cap of $28.95 million, a PE ratio of -2.60 and a beta of 0.81. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.54 and a quick ratio of 0.85. The stock has a 50-day moving average price of $1.64 and a 200-day moving average price of $1.89. IRIDEX has a 1 year low of $1.27 and a 1 year high of $3.65.

IRIDEX (NASDAQ:IRIX) last posted its earnings results on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The business had revenue of $11.58 million during the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same period last year, the firm posted ($0.11) earnings per share.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.